CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, February 9, 2024

In accordance with Article 226 of the recast Spanish Securities Market Act (*Ley del Mercado de Valores*), is hereby reported the following:

INSIDE INFORMATION

Sylentis, S.A.U., a wholly owned subsidiairy of Pharma Mar, announces that has obtained the results of the Phase III SYL10111_V (tivanisiran) clinical trial for the treatment of dry-eye associated with Sjögren's Syndrome. The primary endpoint was to evaluate the efficacy (signs and symptoms) and was not met.

The trial was a randomized, double-masked, placebo-controlled study conducted in more than 40 hospitals in the United States and 8 in Spain involving 203 patients.

Please find attached press release that will be distributed to the media today.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

Sylentis, a PharmaMar Group company, announces the results of the Phase III SYL1001_V trial with tivanisiran for the treatment of dry-eye disease associated with Sjögren's Syndrome

- **The study that evaluated the efficacy of the drug did not meet the primary endpoint.**

Madrid, February 9th, 2024. – Sylentis, a wholly owned subsidiary of PharmaMar (MSE:PHM), has obtained the results of the Phase III SYL10111_V (tivanisiran) clinical trial for the treatment of dry-eye associated with Sjögren's Syndrome. The primary endpoint was to evaluate the efficacy (signs and symptoms) and was not met.

The trial was a randomized, double-masked, placebo-controlled study conducted in more than 40 hospitals in the United States and 8 in Spain involving 203 patients.

Sylentis would like to thank the patients, families, the hospitals, caregivers and the medical teams that have made it possible to carry out this trial.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself and with different

partners. Zepzelca® (lurbinectedin) in the US and Aplidin® (plitidepsin) in Australia under different partner agreements. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54. It also has a preclinical and clinical program in virology. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com

About Sylentis

Sylentis is a pharmaceutical company that develops innovative therapies based on gene silencing technologies or RNAi. This technology enables the design of molecules capable of selectively inhibiting the synthesis of disease-causing proteins. Sylentis has developed numerous therapies based on this novel technology and currently has a strong program in ophthalmology with one candidate in Phase III clinical trials: tivanisiran, for the treatment of dry eye. Sylentis is also researching and developing other new products for the treatment of various eye diseases such as ocular allergies and retinal diseases. For more information, visit www.sylentis.com.

About tivanisiran (SYL1001)

Tivanisiran is a drug based on RNAi that is administered as preservative-free eye drops; it selectively inhibits production of the transient receptor potential cation channel (TRPV1). These receptors are ion channels that mediate the transmission of ocular pain. Tivanisiran is a small synthetic double-stranded RNA oligonucleotide (siRNA) with a novel and highly selective mechanism of action. Non-clinical studies conducted by Sylentis with tivanisiran have demonstrated it has a high ability to inhibit this specific target and block the perception of ocular pain in animals.

Tivanisiran is a product under development for the treatment of signs and symptoms related to dry eye syndrome and has the potential to be developed for other pathologies that cause ocular pain (corneal lesions, refractive surgery, etc.).

About RNA interference (RNAi)

RNA interference is a technology that seeks to reduce abnormal protein production by silencing messenger RNA. RNAi represents a breakthrough as a new mechanism of action to address numerous pathologies. Some pathologies, such as age-related macular degeneration, are caused by an alteration of certain proteins. This technology can act by reducing or controlling in a very specific way the production of the proteins involved in each pathology. Compounds based on RNAi technology tend to have a longer effect than traditional drugs and few side effects, due to their high specificity.

Media Contact:

Lara Vadillo – Communication Director lvadillo@pharmamar.com
Miriam Collados Gordo – Corporate Communication Manager mcollados@pharmamar.com
Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– VP, Capital Markets & Investor Relations Director
Natalia Amo – Capital Markets & Investor Relations
investorrelations@pharmamar.com

Phone: +34 914444500

Or please visit our website at www.pharmamar.com